Hepatocellular carcinoma
Conditions
Interventions
Administration via the catheater inserted into the hepatic artery or the implanted port of Miriplatin(65mg/m2,ia,/day) / 4 weeks. And administration sorafenib( 400~800mg /body/day ) at once.
Sponsors
Division of Gastroenterology,Kurume university School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histrogically or clinically confirmed hepatocellular carcinoma. 2.Advanced HCC no indication for liver transplantation or hepatic resection. 3.Age : 20 years old <= 4.EOCG performance status is 0 or 1. 5.Life expectancy is more than 3 months. 6.Sufficient function of main organ and conditions filled the following criteria. WBC : 2000 /mm3L <= Hb : 8.5 g/dL <= Plt : 50000 / mm3L <= S-Total Bilirubin : 2.0 mg/dL >= S-Albumin : 3.0 g/dL<= S-Creatinine : 1.5 mg/dL >= Without uncontrolled ascites and hepatic encephalopathy Ejection fraction : 45% <= PaO2 : 60mmHg <= 7.Written informed consent was obtained.
Exclusion criteria
Exclusion criteria: 1.Previous hepatic resection or RFA within 4 weeks. 2.Patients with active double cancers. 3.Patients with concurrent infections 4.Patients with hypersensitivity to Miliplatin and contrast medium of iodine. 5.Pregnant, lacting women or women with suspected pregnancy. 6.Inappropriate patients for this study judged by physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complication | — |
Secondary
| Measure | Time frame |
|---|---|
| Response evaluation , overall survival | — |
Countries
Japan
Contacts
Public ContactHiroaki Nagamatsu
Yame General Hospital Department of Hepatology
Outcome results
None listed